Dexcom Inc at Raymond James Institutional Investors Conference (Virtual) Transcript
Okay. Good morning. I think we're live here. My name is Jayson Bedford. I'm the med device analyst here at Raymond James. Thank you for sharing a portion of your day with us here at the 42nd Annual Raymond James Institutional Investors Conference. We're privileged to have with us today the management team from DexCom. Specifically, we have Jereme Sylvain, SVP Finance, Chief Accounting Officer, and Sean Christensen, Head of IR.
So we're going to do a full fireside chat here, and I realize that you guys have covered a lot of topics over the last couple of weeks. But I'd like to cover 3 big topics: G7; awareness, specifically as it relates to the current business; and then maybe new market opportunities.
Questions & Answers
So let's start with G7. You mentioned on the last call that you've completed
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |